Sinomed Files for Hong Kong IPO, Eyes A+H Dual Listing

Sinomed, a STAR Market-listed firm, submitted a prospectus to the Hong Kong Stock Exchange for an A+H dual listing. CMB International is the sole sponsor. The company posted RMB 525 million in operating revenue in 2025.

Despite turning profitable, Sinomed faces a looming ceiling in its coronary business and unresolved financial risks that could weigh on its Hong Kong debut.

The development adds to a wider Hong Kong capital markets story in which companies are being judged on execution, capital access, regulatory fit and the credibility of their regional expansion plans.

For business readers, the important question is whether this becomes an isolated announcement or part of a more durable operating pattern across customers, financing channels, partners and public-market expectations.